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ABSTRACT:
Efflux transporters such as P-glycoprotein and multidrug resis-
tance-associated proteins (MRPs) in the intestinal wall restrict
intestinal drug transport. To overcome this limitation for enteral
drug absorption, galenical targeting approaches have been pro-
posed for site-specific luminal drug release in segments of the gut,
where expression of the respective absorption-limiting transporter
is minimal. Therefore, expression of multidrug resistance gene 1
(MDR1) and MRP1-5 was systematically investigated in 10 healthy
subjects. Biopsies were taken from different segments of the gas-
trointestinal tract (from duodenum and terminal ileum, as well as
ascending, transverse, descending, and sigmoid colon). Gene ex-
pression was investigated by quantitative real-time PCR (TaqMan).
MRP3 appeared to be the most abundantly expressed transporter
in investigated parts of the human intestine, except for the terminal
ileum, where MDR1 showed the highest expression. The ranking of
transporter gene expression in the duodenum was MRP3 
MDR1 > MRP2 > MRP5 > MRP4 > MRP1. In the terminal ileum, the
ranking order was as follows: MDR1 > MRP3  MRP1  MRP5 
MRP4 > MRP2. In all segments of the colon (ascending, trans-
verse, descending, and sigmoid colon), the transporter gene ex-
pression showed the following order: MRP3  MDR1 > MRP4 
MRP5 > MRP1  MRP2. We have shown, for the first time, sys-
tematic site-specific expression of MDR1 and MRP mRNA along
the gastrointestinal tract in humans. All transporters showed al-
terations in their expression levels from the duodenum to sigmoid
colon. The most pronounced changes were observed for MRP2,
with high levels in the small intestine and hardly any expression in
colonic segments. This knowledge may be useful to develop new
targeting strategies for enteral drug delivery.
Efflux transporters in the intestinal wall form a barrier to cellular
accumulation of toxins as well as to drug absorption (Schinkel, 1997).
Important efflux proteins in the gut are P-glycoprotein [gene product
of the multidrug resistance 1 (MDR1) gene] and multidrug resistance-
associated protein (MRP) transporters. They belong to the superfamily
of ATP-binding cassette (ABC) transporters. ABC transporters medi-
ate the translocation of a wide variety of substances across cellular
membranes using ATP hydrolysis (Horio et al., 1988; Senior et al.,
1995). The expression of ABC transporter genes is widespread
throughout many tissues, most notably in excretory sites such as the
liver, kidney, blood-brain barrier, and intestine. Therefore, they play
a critical role in absorption and tissue distribution of orally adminis-
tered drugs (Schuetz et al., 1998; Ambudkar et al., 1999). Due to their
broad substrate specificity, they may influence the pharmacokinetics
of many chemically unrelated substances (e.g., HIV drugs, anticancer
drugs, endogenous compounds) (Lee et al., 1997; Schinkel, 1998;
Schuetz et al., 1999; Borst et al., 2000). MDR1 preferentially extrudes
large hydrophobic, positively charged molecules, whereas the mem-
bers of the MRP family extrude both hydrophobic uncharged mole-
cules and water-soluble anionic compounds.
There is little knowledge about the expression pattern of those ABC
transporters along the human intestine. Taipalensuu et al. (2001)
investigated gene expression of 10 ABC transporters in jejunal biop-
sies from healthy subjects. The highest expression was shown for
breast cancer resistance protein and MRP2. Nakamura et al. (2002)
investigated the expression of three ABC transporters in duodenal and
colorectal tissues in humans. In comparison to duodenum, in colon
they found a decrease in MDR1 expression, equal levels of MRP1,
and a strong decrease in MRP2 expression. However, this comparison
was not obtained in the same subjects. Therefore, the intraindividual
expression differences between these transporters could not be as-
sessed.
Knowledge of the topographical distribution may be important for
the development of specific galenical targeting approaches, which
may be utilized to improve intestinal absorption of drugs. Therefore,
in this study, the expression of MDR1 and MRP1-5 genes was
investigated in the human intestine of 10 healthy subjects.
Materials and Methods
Intestinal biopsies were obtained from a group of 10 healthy subjects (5
female, 5 male, aged 50–76 years, average age 62 years, no medication), which
served as a control group in a clinical study designed to investigate the regional
expression of different genes in patients with inflammatory bowel disease. The
study protocol included specifically the investigation of drug-transporting
proteins and was approved by the local ethical committee. Informed consent
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0090-9556/05/3302-219–224$20.00
DRUG METABOLISM AND DISPOSITION Vol. 33, No. 2
Copyright © 2005 by The American Society for Pharmacology and Experimental Therapeutics 1354/1191268
DMD 33:219–224, 2005 Printed in U.S.A.
219
was obtained from all subjects prior to inclusion. No macroscopically patho-
logical findings were observed during endoscopies in these subjects. Three to
four biopsies were obtained from duodenum, terminal ileum, ascending colon,
transverse colon, descending colon, and sigmoid colon. Due to low enterocyte
content, duodenal biopsies from one subject had to be discarded, leading to
nine duodenal samples.
Preparation of Samples. The samples were immediately submerged in a
tube with RNAlater (Ambion, Austin, TX) and stored at 80°C until further
processing. For RNA isolation, two biopsies from each intestinal region were
homogenized for 30 s (Polytron PT 2100; Kinematika AG, Littau, Switzerland)
and RNA was extracted using the RNeasy Mini Kit (QIAGEN GmbH, Hilden,
Germany) following the instructions provided by the manufacturer. RNA was
quantified with a GeneQuant photometer (Pfizer, Inc., Täby, Sweden). After
DNase I digestion (Invitrogen, Basel, Switzerland), 1.5 g of total RNA was
reverse-transcribed by SuperScript (Invitrogen) according to the manufactur-
er’s protocol, using random hexamers as primers.
TaqMan analysis was carried out on a 7900HT Sequence Detection System
(Applied Biosystems, Rotkreuz, Switzerland). PCR conditions were 10 min at
95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Each TaqMan
reaction contained 25 ng of cDNA in a total volume of 25 l. TaqMan
Universal PCR Mastermix from Applied Biosystems was used. The concen-
trations of primers and probes were 900 nM and 225 nM, respectively. Primers
and probes were designed according to the guidelines of Applied Biosystems
with help of Primer Express 2.0 software (Table 1). Primers were synthesized
by Invitrogen (Basel, Switzerland) and probes by Eurogentec (Seraing, Bel-
gium). For absolute mRNA quantification, we used external standard curves.
The standards were reverse transcription-PCR products of the appropriate gene
(Table1). These cDNA standards were purified by running a 1.5% agarose gel
and by a subsequent gel extraction (gel extraction kit, QIAGEN GmbH). They
were quantified using the PicoGreen reagent (Molecular Probes, Eugene, OR)
and were checked by sequencing (Microsynth GmbH, Balgach, Switzerland).
All samples were run in triplicates, and non-reverse-transcribed RNA served as
a negative control.
For each sample, the number of transporter transcripts (MDR1, MRP1–5)
and the number of villin transcripts were determined. By calculating the ratio
of transporter/villin mRNA, the transporter expression was normalized. En-
terocytes represent only a small fraction of the cells obtained in an intestinal
biopsy. Determination of villin, an enterocyte-specific, constitutively ex-
pressed protein, can be used to control for the variation of enterocyte content
in biopsy (Lown et al., 1994). Therefore, transporter mRNA concentrations
were expressed as a ratio with the villin levels of the same samples. These
villin-corrected values provide a relative measure of enterocyte concentration
(Lown et al., 1997). Results with this approach have already been published
(Taipalensuu et al., 2001; Mouly and Paine, 2003).
Statistical Analysis. Gene expression was compared between the different
intestinal segments by analysis of variance. In the case of significant differ-
ences, all segments were compared with the expression in duodenum using
two-sided Dunnett’s multicomparison t test. The level of significance was P 
0.05. Comparisons were performed using SPSS for Windows software (version
11.0; SPSS Inc., Chicago, IL).
Results
There was a considerable interindividual variability of transporter
gene expression amounting on average to 34% (CV%). Figure 1
displays the expression and ranking of all transporters in the analyzed
tissues normalized to villin. MRP3 appeared to be the most abun-
dantly expressed transporter in the investigated parts of the human
intestine, except for the terminal ileum, where MDR1 showed the
highest expression. The ranking of transporter gene expression in the
duodenum was MRP3  MDR1  MRP2  MRP5  MRP4 
MRP1. In the terminal ileum the ranking order was as follows:
TABLE 1
Primers and probes
Primers for cDNA Standards
Gene Forward Primer Reverse Primer
MDR1 (ABCB1) 5-ACAGTCCAGCTGATGCAGAGG-3 5-CCTTATCCAGAGCCACCTGAAC-3
MRP1 (ABCC1) 5-CACACTGAATGGCATCACCTTC-3 5-CCTTCTCGCCAATCTCTGTCC-3
MRP2 (ABCC2) 5-CCAATCTACTCTCACTTCAGCGAGA-3 5-AGATCCAGCTCAGGTCGGTACC-3
MRP3 (ABCC3) 5-TCTATGCAGCCACATCACGG-3 5-GTCACCTGCAAGGAGTAGGACAC-3
MRP4 (ABCC4) 5-AAGTGAACAACCTCCAGTTCCA-3 5-CCGGAGCTTTCAGAATTGAC-3
MRP5 (ABCC5) 5-CTAGAGAGACTGTGGCAAGAAGAGC-3 5-AAATGCCATGGTTAGGATGGC-3
Villin (VIL1) 5-AGAAAGCCAATGAGCAGGAGAA-3 5-ATGGATGTGGCATCGAACTTC-3
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MDR1  MRP3  MRP1  MRP5  MRP4  MRP2. In all
segments of the colon (ascending, transverse, descending, and sig-
moid colon), the transporter expression showed the following order:
MRP3  MDR1  MRP4  MRP5  MRP1  MRP2.
Figure 2 shows the expression pattern of each individual transporter
from the duodenum to the sigmoid colon normalized to villin. Com-
pared with the duodenum, the expression of MDR1 was 4-fold higher
in the terminal ileum and approximately 2-fold higher in the colonic
segments. MRP1 exhibited a 2- to 3-fold higher expression in both the
terminal ileum and colon compared with duodenum. MRP2 showed
highest expression in the duodenum, half-levels in the terminal ileum,
and hardly any MRP2 transcripts in each colonic segment. MRP3,
MRP4, and MRP5 exhibited a similar expression pattern with equal
levels in the duodenum and terminal ileum, but a 2- to 3-fold increase
in the colon. Within the colon, MRP1, MRP3, and MRP5 showed an
expression pattern with decreasing levels from proximal to distal,
whereas MDR1, MRP2, and MRP4 levels remained rather constant.
Discussion
Only little information is available about the expression of ABC
transporters along the intestinal tract. Available information relates
mainly to MDR1 and MRP2 expression (Dietrich et al., 2003; Lindell
et al., 2003). Furthermore, previous studies have focused on isolated
parts of the intestine (Taipalensuu et al., 2001; Lindell et al., 2003), on
animal models (Achira et al., 2002; Takara et al., 2003), or on cancer
cells (Nakamura et al., 2002; Li et al., 2003; Pfrunder et al., 2003).
Here, we present a systematic investigation of multidrug resistance
protein mRNA expression in various parts of the human intestine from
proximal to distal within the same subject. One drawback of the study
is the lack of samples from the jejunum, an important site for drug
absorption. The subjects in our study underwent combined gastros-
copy and colonoscopy procedures for screening of gastrointestinal
cancer. Therefore, an additional jejunoscopy was not performed.
However, Taipalensuu et al. (2001) focused on the human jejunum
and found a transporter expression with the following ranking:
MRP2  MDR1  MRP3  MRP5  MRP1  MRP4. Besides the
high MRP2 levels, the transporter expression pattern in the jejunum
shows strong similarity to the pattern we found in the terminal ileum,
which is conclusive because of the proximity of these tissues.
It is suggested that MDR1 physiologically functions as a gatekeeper
against xenobiotics in the gut. The bioavailability of many drugs is
reduced due to MDR1 efflux. MDR1 shows an extremely broad
substrate specificity, including anticancer agents, antibiotics, antivi-
rals, calcium channel blockers, and immunosuppressants. With re-
spect to the expression of MDR1 in the human intestine, an increase
from proximal to distal was stated, with the highest expression levels
documented in the colon (Fricker et al., 1996; Dietrich et al., 2003;
Chan et al., 2004). In mice, however, Chianale et al. (1995) found the
highest levels of mdr3 mRNA in the ileum. In the rat intestine, the
P-glycoprotein-mediated drug efflux showed highest activity in the
ileum as well (Stephens et al., 2001). We could also demonstrate, in
humans, higher MDR1 mRNA levels in the terminal ileum compared
with the duodenum. These results are consistent with human data from
Mouly and Pain (2003), who reported an increase in P-glycoprotein
from duodenum to ileum. Additionally, our results indicate the highest
MDR1 expression in the terminal ileum within the investigated seg-
ments of the human intestine. It appeared to be 4-fold higher in the
terminal ileum compared with the duodenum and 2-fold higher com-
pared with the colon. Moreover, MDR1 was the most abundantly
expressed transporter in the terminal ileum compared with all other
ABC transporters that were analyzed in this study.
MRP1 showed the lowest variation in mRNA levels within the
intestinal tract. This is in good agreement with the fact that MRP1 is
expressed ubiquitously. Physiologically important substrates for
MRP1 include glutathione S-conjugates such as leukotriene C4, as
well as bilirubin glucuronides (Keppler et al., 1998). In addition,
anionic drugs and drugs conjugated to glutathione, like methotrexate
or arsenite, are also transported by MRP1 (Bakos et al., 2000; Vernhet
et al., 2000).
A previous study revealed that MRP2 is the ABC transporter with
FIG. 1. mRNA expression of MDR1 and MRP1-5 genes in different gut segments normalized to villin expression. Data represent means (S.E.M.) of biopsies from 10
healthy subjects, except duodenum, where biopsies from 9 subjects were used.
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the highest expression besides breast cancer resistance protein in
the human jejunum (Taipalensuu et al., 2001). We found relatively
low MRP2 levels in the human duodenum and even lower levels in
the terminal ileum, but almost no MRP2 expression in the entire
colon. These results were also found in the rat intestine (Mottino et
al., 2000; Rost et al., 2002), but up to now, they were not con-
firmed in humans. The results are also consistent with the expres-
sion pattern of glutathione S-transferase in the human gastrointes-
tinal tract mucosa (Coles et al., 2002). This phase II metabolizing
enzyme provides the conjugated compounds for subsequent export
by MRP2 or MRP1. The substrate specificity of MRP2 is similar to
that of MRP1, and includes glutathione conjugates, bilirubin glu-
curonides, and a number of drugs and their conjugated drug me-
tabolites (Jedlitschky et al., 1997; Kawabe et al., 1999). These
drugs include pravastatin, temocaprilat, irinotecan, SN-38, arsen-
ite, cisplatin, methotrexate, vincristine, saquinavir, and ceftriaxone
(Kusuhara and Sugiyama, 2002; Dietrich et al., 2003). Regarding
the amount of drugs transported by MRP2, a drug targeting which
FIG. 2. Transporter-specific gene expression in different gut segments normalized to villin expression. A, MDR1; B, MRP1; C, MRP2; D, MRP3; E, MRP4; and F, MRP5.
Data represent means (S.E.M.) of biopsies from 10 healthy subjects, except duodenum, where biopsies from 9 subjects were used.
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circumvents absorption sites with high MRP2 expression would be
of benefit, especially for drugs with low bioavailability.
MRP3 transports a wide range of bile salts and seems to be
involved in their reabsorption (Hirohashi et al., 2000). MRP3 trans-
fection of cell lines conferred resistance to epipodophyllotoxins, vin-
cristine and methotrexate (Kool et al., 1999). For MRP3, Rost et al.
(2002) showed low expression in the rat duodenum and high expres-
sion in the ileum and colon. Our human data indicate low MRP3
levels in the duodenum as well as in the terminal ileum but also high
expression in the colon. Within the colon, MRP3 expression dimin-
ished slightly from proximal to distal segments. This reduction in
transporter expression from ascending to sigmoid colon was observed
for MRP1, MRP3, and MRP5. Interestingly, all of these transporters
are located on the basolateral membrane. For MDR1, MRP2, and
MRP4, probably located on the apical membrane (Chan et al., 2004),
we observed rather constant expression levels throughout the entire
colon.
With respect to MRP4, we found equal expression levels in the
duodenum and the terminal ileum but a 3-fold increase in the colon.
To our knowledge, there is no previous publication on the MRP4
expression in the colon. The significance of MRP4 in drug transport
is at present unclear. However, an overexpression of MRP4 severely
impaired the antiviral efficacy of adefovir, azidothymidine, and other
nucleoside analogs in cell lines (Schuetz et al., 1999). Other substrates
include folic acid, bile acids, methotrexate, and 6-mercaptopurine
(Wielinga et al., 2002; Chan et al., 2004). A physiological role of
MRP4 might be the release of prostaglandins from cells (Reid et al.,
2003).
MRP5 expression appeared to be concordant to MRP4 expression
with low levels in the duodenum and the terminal ileum, but a 2-fold
increase in the different colon segments. Both transporters have an
affinity to nucleotide-based substrates. There are no reports, at
present, which could suggest a role for MRP5 in intestinal drug
disposition. Experiments with transfected cells showed enhanced ef-
flux of 2,4-dinitrophenyl-S-glutathione, adefovir, and the purine ana-
logs 6-mercaptopurine and thioguanine (Wijnholds et al., 2000).
Jedlitschky et al. (2000) demonstrated that MRP5 transports the cyclic
nucleotides cAMP and cGMP, but the physiological function of this
transporter remains to be elucidated.
Although our results indicate significant changes of MDR1 and
MRP1-5 gene expression in investigated parts of the human intestine,
this does not necessarily correlate with protein expression or function.
Additional studies regarding the effect of expression on protein levels
are therefore required.
The impact of these transporters should be evaluated for drugs
permeating epithelial barriers, especially during pharmacological de-
velopment of novel classes of therapeutic compounds. Selectivity of
inhibitors, in particular, for human efflux transporters located at the
apical mucosal membrane (such as MDR1, MRP2, and MRP4), re-
mains to be examined, and further studies are required. Therefore, the
knowledge of the transporter expression throughout the human intes-
tine might be of special value.
Conclusion
We have shown, for the first time, systematic site-specific expres-
sion of MDR1 and MRP isoforms along the gastrointestinal tract in
humans. All transporters showed alterations in their expression levels
from the duodenum to the sigmoid colon. The most pronounced
changes were observed for MRP2, with high levels in the small
intestine and hardly any expression in colonic segments. This knowl-
edge may be useful to develop new targeting strategies for enteral
drug delivery.
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